Process of reporting serious adverse events (SAE) during a regulatory Download Scientific Diagram Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab Under reporting of harm in clinical trials The Lancet Oncology Sermorelin: Benefits, FDA Status & Safety in 2025 Healthon Clinical spectrum and evolution of immune checkpoint inhibitors toxicities over a decadea worldwide perspective eClinicalMedicine Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports